Bugworks Research Inc. aims to tackle this global Anti-microbial Resistance (AMR) crisis by developing a novel class of antibiotics exhibiting broad-spectrum activity against Gram-negative and Gram-positive infections. Using the proprietary platform, Bugworks has come up with a first-in-class antibiotic series named GYROX that is effective on all known classes of drug-resistant bacteria. Bugworks is the first Asian company to win the prestigious CARB‑X grant, amounting to over $10M.

Date- 26^th November

Time- 6 – 7 pm IST

Registration link — https://​lnkd​.in/​g​3​M​-cFAf